CSIMarket Company Name, Ticker, Industry, else..
 
Hookipa Pharma inc   (NASDAQ: HOOK)
 
Price: $1.1500 $1.15 %
Day's High: $1.149999976158142 Week Perf: 0.00
Day's Low: $ 1.15 30 Day Perf: 1.77 %
Volume (M): 0 52 Wk High: $ 1.20
Volume (M$): $ 0 52 Wk Avg: $1.01
Open: $1.15 52 Wk Low: $0.83



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 13
 Employees 28
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -73
 Cash Flow (TTM) (Millions $) -54
 Capital Exp. (TTM) (Millions $) 0

Business Description


Hookipa Pharma Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immunotherapeutics for cancer and infectious diseases. The company is known for its proprietary technology platform, Vaxwave®, which is designed to stimulate both the innate and adaptive immune systems. Hookipa Pharma's goal is to create a new class of immunotherapeutics that are safer and more effective than traditional approaches. The company is headquartered in New York, United States.


   Company Address: 350 Fifth Avenue, 72nd Floor, Suite 7240 New York 10118 NY
   Company Phone Number: 890 63 60   Stock Exchange / Ticker: NASDAQ HOOK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -0.7%    
JNJ   -2.63%    
LLY   -7.23%    
MRK   -1.92%    
REGN   -3.55%    
TAK   -1.43%    
• View Complete Report
   



Merger and Acquisition

HOOKIPA Pharma Inc. (HOOKIPA) Statement regarding potential combination for Poolbeg Pharma plc (Poolbeg)

Published Thu, Feb 20 2025 4:42 PM UTC

New York and Vienna, Austria: Insights into Hookipa Pharma s Strategic Movements and Market RegulationsFOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.As of February 20, 2025, the biopharmaceutical lan...
Merger and Acquisition

Potential Merger: Poolbeg and HOOKIPA Pharma Explore Strategic Combination Amid Struggling Share Prices

Published Tue, Jan 7 2025 7:00 AM UTC

The Landscape of Pharmaceutical Innovation: An Important Update on Poolbeg Pharma plc and HOOKIPA Pharma Inc.In the fast-paced world of biopharmaceuticals, strategic partnerships and potential mergers can significantly shape the landscape, offering companies new avenues for growth, innovation, and market penetration. Recently, Poolbeg Pharma plc (Poolbeg) and HOOKIPA Pharma ...
Merger and Acquisition

Understanding Hookipa Pharma: Implications of Recent UK Disclosure Requirements and Market Regulations

Published Fri, Jan 10 2025 7:00 AM UTC

Understanding Hookipa Pharma: Implications of Recent U.K. Disclosure Requirements and Market RegulationsAs the pharmaceutical landscape continues to evolve, companies must navigate complex regulatory frameworks, particularly when considering cross-border operations and shareholders. HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company specializing in the development of innovative ...
Stock Market Announcement

HOOKIPA Pharma Announce Key U.K. Disclosure Requirements: Implications for Shareholders and Market Performance

Published Tue, Jan 7 2025 9:05 PM UTC

In a recent press release dated January 7, 2025, HOOKIPA Pharma Inc. (NASDAQ: HOOK) informed shareholders about important updates regarding U.K. disclosure requirements. As a clinical-stage biopharmaceutical company specializing in next-generation immunotherapeutics, HOOKIPA is currently focused on innovative treatments for cancer and serious infectious diseases. Key Facts ...
Merger and Acquisition

HOOKIPA Pharma Inc. and Poolbeg Pharma Set to Revolutionize Biotech: A Strategic Collaboration Announcement,

Published Mon, Jan 6 2025 7:00 AM UTC

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.Innovative Pathways: HOOKIPA Pharma Inc. and Poolbeg Pharma Unite to Transform Biotech LandscapeAs the biotech sector continues to evolve at an incredible pace, two players, HOO...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.54
Price to Sales (Expected) -
Price to Book 0.42
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.42
Working Capital Ratio 3.61
Leverage Ratio (MRQ) 0.79
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.84 $
Revenues (TTM) 0.75 $
Cash Flow (TTM) -
Cash 3.21 $
Book Value 2.72 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 333,964
Net Income per Employee (TTM) -2,618,321
Receivable Turnover Ratio (TTM) 30.14
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.1

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -891.92 %
Net Margin (MRQ) -769.81 %
Net Cash Flow Margin (MRQ) 1.6 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Hookipa Pharma Inc's Segments
Single segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.